title: Frustrated by regulatory delays at FDA, biotech companies warm to user fees.
authors.forename: D
authors.initials: D
authors.lastname: Gershon
mesh_terms: D001709:Biotechnology / Q000191:economics*; D004345:Drug Industry / Q000191:economics*; D014481:United States; D014486:United States Food and Drug Administration / Q000191:economics*